氨磺必利和喹硫平治疗精神分裂症临床疗效对照研究  

Study on the clinical efficacy of controlling schizophrenia with amisulpride and quetiapine

作　　者：刘志玲[1] 黄史青[1] 黄慈芬[1] 曾海燕[1] 廖柳苑 

机构地区：[1]佛山市第三人民医院一科,广东528041

出　　处：《齐齐哈尔医学院学报》2015年第5期703-704,共2页Journal of Qiqihar Medical University

摘　　要：目的探讨氨磺必利和喹硫平对精神分裂症临床疗效及安全性。方法对符合CCMD-3关于精神分裂症诊断的住院患者进行随机分组,研究组(42例)用氨磺必利治疗;对照组(40例)用喹硫平治疗;两组于入组时、4周末、8周末进行阳性和阴性综合征量表(PANSS)评及不良反应进行评定。结果研究组和对照组PANSS总分均显著下降(P<0.05),研究组总体治疗有效率90.5%,对照组总体有效率75.0%,研究组疗效优于对照组(P<0.05)。研究组和对照组在不良反应比较无显著性(P>0.05)。结论氨磺必利治疗精神分裂疗效好,且不良反应轻,值得临床推广应用。Objective We aimed to explore the clinical efficacy and safety of amisulpride and quetiapine in treating schizophrenia. Methods The schizophrenia patients, those who accordance with the CCMD - 3 standard, were randomly divided into two groups. Patients in study group （42 cases ） were treated with amisulpride, while the patients in control group （40 cases） were treated with quetiapine. All of them received Positive and Negative Syndrome Scale （PANSS） assessment at the time points admitted and 4th and 8th weekends after admitted, adverse reactions were assessed. Results Total scores of PANSS of study group and the control group were significantly decreased after the treatment（P 〈 0. 05 ）. The total effective rate of treatment group was 90. 1%, it was significantly higher than that of control group（75.1% ）, the difference was statistically significant （P 〈 0. 05）. The difference of incidence of adverse reaction between study group and the control group was not statistically significant （P 〉 0. 05 ）. Conclusions Amisulpride was proved to have better curative effect in the treatment of schizophrenia and causes less adverse reactions, it is worthy of clinical application.

关 键 词：精神分裂症 氨磺必利 喹硫平 临床疗效 

分 类 号：R978.7[医药卫生—药品]